Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 102 entries
Sorted by: Best Match Show Resources per page
Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.

Therapeutic advances in medical oncology

Alese OB, El-Rayes BF, Sica G, Zhang G, Alexis D, La Rosa FG, Varella-Garcia M, Chen Z, Rossi MR, Adsay NV, Khuri FR, Owonikoko TK.
PMID: 25755678
Ther Adv Med Oncol. 2015 Mar;7(2):56-62. doi: 10.1177/1758834014567117.

OBJECTIVES: ALK-EML4 translocation is an established driver aberration in non-small cell lung cancer (NSCLC), with reported predilection for cases with signet ring histology. We assessed the presence of anaplastic lymphoma kinase (ALK) gene rearrangements in signet ring cancers arising...

Cite
Alese OB, El-Rayes BF, Sica G, et al. Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Ther Adv Med Oncol. 2015;7(2):56-62doi: 10.1177/1758834014567117.
Alese, O. B., El-Rayes, B. F., Sica, G., Zhang, G., Alexis, D., La Rosa, F. G., Varella-Garcia, M., Chen, Z., Rossi, M. R., Adsay, N. V., Khuri, F. R., & Owonikoko, T. K. (2015). Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Therapeutic advances in medical oncology, 7(2), 56-62. https://doi.org/10.1177/1758834014567117
Alese, Olatunji B, et al. "Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract." Therapeutic advances in medical oncology vol. 7,2 (2015): 56-62. doi: https://doi.org/10.1177/1758834014567117
Alese OB, El-Rayes BF, Sica G, Zhang G, Alexis D, La Rosa FG, Varella-Garcia M, Chen Z, Rossi MR, Adsay NV, Khuri FR, Owonikoko TK. Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Ther Adv Med Oncol. 2015 Mar;7(2):56-62. doi: 10.1177/1758834014567117. PMID: 25755678; PMCID: PMC4346214.
Copy Download .nbib Format: NLM
TNFRSF10C copy number variation is associated with metastatic colorectal cancer.

Journal of gastrointestinal oncology

Tanenbaum DG, Hall WA, Colbert LE, Bastien AJ, Brat DJ, Kong J, Kim S, Dwivedi B, Kowalski J, Landry JC, Yu DS.
PMID: 27284460
J Gastrointest Oncol. 2016 Jun;7(3):306-14. doi: 10.21037/jgo.2015.11.04.

BACKGROUND: Genetic markers for distant metastatic disease in patients with colorectal cancer (CRC) are not well defined. Identification of genetic alterations associated with metastatic CRC could help to guide systemic and local treatment strategies. We evaluated the association of...

Cite
Tanenbaum DG, Hall WA, Colbert LE, et al. TNFRSF10C copy number variation is associated with metastatic colorectal cancer. J Gastrointest Oncol. 2016;7(3):306-14doi: 10.21037/jgo.2015.11.04.
Tanenbaum, D. G., Hall, W. A., Colbert, L. E., Bastien, A. J., Brat, D. J., Kong, J., Kim, S., Dwivedi, B., Kowalski, J., Landry, J. C., & Yu, D. S. (2016). TNFRSF10C copy number variation is associated with metastatic colorectal cancer. Journal of gastrointestinal oncology, 7(3), 306-14. https://doi.org/10.21037/jgo.2015.11.04
Tanenbaum, Daniel G, et al. "TNFRSF10C copy number variation is associated with metastatic colorectal cancer." Journal of gastrointestinal oncology vol. 7,3 (2016): 306-14. doi: https://doi.org/10.21037/jgo.2015.11.04
Tanenbaum DG, Hall WA, Colbert LE, Bastien AJ, Brat DJ, Kong J, Kim S, Dwivedi B, Kowalski J, Landry JC, Yu DS. TNFRSF10C copy number variation is associated with metastatic colorectal cancer. J Gastrointest Oncol. 2016 Jun;7(3):306-14. doi: 10.21037/jgo.2015.11.04. PMID: 27284460; PMCID: PMC4880759.
Copy Download .nbib Format: NLM
Identification of human plasma cells with a lamprey monoclonal antibody.

JCI insight

Yu C, Liu Y, Chan JTH, Tong J, Li Z, Shi M, Davani D, Parsons M, Khan S, Zhan W, Kyu S, Grunebaum E, Campisi P, Propst EJ, Jaye DL, Trudel S, Moran MF, Ostrowski M, Herrin BR, Lee FE, Sanz I, Cooper MD, Ehrhardt GR.
PMID: 27152361
JCI Insight. 2016;1(3). doi: 10.1172/jci.insight.84738. Epub 2016 Mar 17.

Ab-producing plasma cells (PCs) serve as key participants in countering pathogenic challenges as well as being contributors to autoimmune and malignant disorders. Thus far, only a limited number of PC-specific markers have been identified. The characterization of the unique...

Cite
Yu C, Liu Y, Chan JTH, et al. Identification of human plasma cells with a lamprey monoclonal antibody. JCI Insight. 2016;1(3)doi: 10.1172/jci.insight.84738.
Yu, C., Liu, Y., Chan, J. T. H., Tong, J., Li, Z., Shi, M., Davani, D., Parsons, M., Khan, S., Zhan, W., Kyu, S., Grunebaum, E., Campisi, P., Propst, E. J., Jaye, D. L., Trudel, S., Moran, M. F., Ostrowski, M., Herrin, B. R., Lee, F. E., Sanz, I., Cooper, M. D., & Ehrhardt, G. R. (2016). Identification of human plasma cells with a lamprey monoclonal antibody. JCI insight, 1(3), . https://doi.org/10.1172/jci.insight.84738
Yu, Cuiling, et al. "Identification of human plasma cells with a lamprey monoclonal antibody." JCI insight vol. 1,3 (2016). doi: https://doi.org/10.1172/jci.insight.84738
Yu C, Liu Y, Chan JTH, Tong J, Li Z, Shi M, Davani D, Parsons M, Khan S, Zhan W, Kyu S, Grunebaum E, Campisi P, Propst EJ, Jaye DL, Trudel S, Moran MF, Ostrowski M, Herrin BR, Lee FE, Sanz I, Cooper MD, Ehrhardt GR. Identification of human plasma cells with a lamprey monoclonal antibody. JCI Insight. 2016;1(3). doi: 10.1172/jci.insight.84738. Epub 2016 Mar 17. PMID: 27152361; PMCID: PMC4854299.
Copy Download .nbib Format: NLM
Locoregional and Distant Recurrence Patterns in Young versus Elderly Women Treated for Breast Cancer.

International journal of breast cancer

Rudra S, Yu DS, Yu ES, Switchenko JM, Mister D, Torres MA.
PMID: 25949828
Int J Breast Cancer. 2015;2015:213123. doi: 10.1155/2015/213123. Epub 2015 Apr 09.

Objective. This study examined recurrence patterns in breast cancer patients younger than age of 40 and older than age of 75, two groups that are underrepresented in clinical trials and not routinely screened by mammography. Methods. The records of...

Cite
Rudra S, Yu DS, Yu ES, et al. Locoregional and Distant Recurrence Patterns in Young versus Elderly Women Treated for Breast Cancer. Int J Breast Cancer. 2015;2015:213123doi: 10.1155/2015/213123.
Rudra, S., Yu, D. S., Yu, E. S., Switchenko, J. M., Mister, D., & Torres, M. A. (2015). Locoregional and Distant Recurrence Patterns in Young versus Elderly Women Treated for Breast Cancer. International journal of breast cancer, 2015213123. https://doi.org/10.1155/2015/213123
Rudra, Soumon, et al. "Locoregional and Distant Recurrence Patterns in Young versus Elderly Women Treated for Breast Cancer." International journal of breast cancer vol. 2015 (2015): 213123. doi: https://doi.org/10.1155/2015/213123
Rudra S, Yu DS, Yu ES, Switchenko JM, Mister D, Torres MA. Locoregional and Distant Recurrence Patterns in Young versus Elderly Women Treated for Breast Cancer. Int J Breast Cancer. 2015;2015:213123. doi: 10.1155/2015/213123. Epub 2015 Apr 09. PMID: 25949828; PMCID: PMC4408642.
Copy Download .nbib Format: NLM
The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma.

Journal of gastrointestinal oncology

Hall WA, Colbert LE, Nickleach D, Switchenko J, Liu Y, Gillespie T, Lipscomb J, Hardy C, Kooby DA, Prabhu RS, Kauh J, Landry JC.
PMID: 24772334
J Gastrointest Oncol. 2014 Apr;5(2):77-85. doi: 10.3978/j.issn.2078-6891.2014.001.

PURPOSE: Radiation therapy (RT) dose escalation in unresectable pancreatic adenocarcinoma (PAC) remains investigational. We examined the association between total RT dose and overall survival (OS) in patients with unresectable PAC.METHODS AND MATERIALS: National cancer data base (NCDB) data were...

Cite
Hall WA, Colbert LE, Nickleach D, et al. The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. J Gastrointest Oncol. 2014;5(2):77-85doi: 10.3978/j.issn.2078-6891.2014.001.
Hall, W. A., Colbert, L. E., Nickleach, D., Switchenko, J., Liu, Y., Gillespie, T., Lipscomb, J., Hardy, C., Kooby, D. A., Prabhu, R. S., Kauh, J., & Landry, J. C. (2014). The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. Journal of gastrointestinal oncology, 5(2), 77-85. https://doi.org/10.3978/j.issn.2078-6891.2014.001
Hall, William A, et al. "The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma." Journal of gastrointestinal oncology vol. 5,2 (2014): 77-85. doi: https://doi.org/10.3978/j.issn.2078-6891.2014.001
Hall WA, Colbert LE, Nickleach D, Switchenko J, Liu Y, Gillespie T, Lipscomb J, Hardy C, Kooby DA, Prabhu RS, Kauh J, Landry JC. The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. J Gastrointest Oncol. 2014 Apr;5(2):77-85. doi: 10.3978/j.issn.2078-6891.2014.001. PMID: 24772334; PMCID: PMC3999628.
Copy Download .nbib Format: NLM
Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines.

Current pharmacogenomics and personalized medicine

Griner SE, Wang KJ, Joshi JP, Nahta R.
PMID: 24179558
Curr Pharmacogenomics Person Med. 2013 Mar 01;11(1):31-41. doi: 10.2174/1875692111311010006.

Acquired resistance to trastuzumab is a clinical problem in the treatment of HER2-over-expressing metastatic breast cancer. Importantly, an earlier report suggested that high body mass index was associated with reduced overall survival and reduced time to progression in patients...

Cite
Griner SE, Wang KJ, Joshi JP, et al. Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines. Curr Pharmacogenomics Person Med. 2013;11(1):31-41doi: 10.2174/1875692111311010006.
Griner, S. E., Wang, K. J., Joshi, J. P., & Nahta, R. (2013). Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines. Current pharmacogenomics and personalized medicine, 11(1), 31-41. https://doi.org/10.2174/1875692111311010006
Griner, Samantha E, et al. "Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines." Current pharmacogenomics and personalized medicine vol. 11,1 (2013): 31-41. doi: https://doi.org/10.2174/1875692111311010006
Griner SE, Wang KJ, Joshi JP, Nahta R. Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines. Curr Pharmacogenomics Person Med. 2013 Mar 01;11(1):31-41. doi: 10.2174/1875692111311010006. PMID: 24179558; PMCID: PMC3811155.
Copy Download .nbib Format: NLM
Tumor margin assessment of surgical tissue specimen of cancer patients using label-free hyperspectral imaging.

Proceedings of SPIE--the International Society for Optical Engineering

Fei B, Lu G, Wang X, Zhang H, Little JV, Magliocca KR, Chen AY.
PMID: 30294063
Proc SPIE Int Soc Opt Eng. 2017 Jan-Feb;10054. doi: 10.1117/12.2249803. Epub 2017 Feb 14.

We are developing label-free hyperspectral imaging (HSI) for tumor margin assessment. HSI data, hypercube (x,y,λ), consists of a series of high-resolution images of the same field of view that are acquired at different wavelengths. Every pixel on the HSI...

Cite
Fei B, Lu G, Wang X, et al. Tumor margin assessment of surgical tissue specimen of cancer patients using label-free hyperspectral imaging. Proc SPIE Int Soc Opt Eng. 2017;10054doi: 10.1117/12.2249803.
Fei, B., Lu, G., Wang, X., Zhang, H., Little, J. V., Magliocca, K. R., & Chen, A. Y. (2017). Tumor margin assessment of surgical tissue specimen of cancer patients using label-free hyperspectral imaging. Proceedings of SPIE--the International Society for Optical Engineering, 10054. https://doi.org/10.1117/12.2249803
Fei, Baowei, et al. "Tumor margin assessment of surgical tissue specimen of cancer patients using label-free hyperspectral imaging." Proceedings of SPIE--the International Society for Optical Engineering vol. 10054 (2017). doi: https://doi.org/10.1117/12.2249803
Fei B, Lu G, Wang X, Zhang H, Little JV, Magliocca KR, Chen AY. Tumor margin assessment of surgical tissue specimen of cancer patients using label-free hyperspectral imaging. Proc SPIE Int Soc Opt Eng. 2017 Jan-Feb;10054. doi: 10.1117/12.2249803. Epub 2017 Feb 14. PMID: 30294063; PMCID: PMC6169990.
Copy Download .nbib Format: NLM
Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis.

Journal of gastrointestinal oncology

Akce M, Jiang R, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF.
PMID: 30788163
J Gastrointest Oncol. 2019 Feb;10(1):85-94. doi: 10.21037/jgo.2018.10.06.

BACKGROUND: Gastric squamous cell carcinoma (GSCC) and gastric adenosquamous carcinoma (GASC) comprise less than 2% of gastric cancers. The current knowledge about clinical presentation, treatment modalities and outcomes of GSCC and GASC is limited. The aim of this study...

Cite
Akce M, Jiang R, Alese OB, et al. Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. J Gastrointest Oncol. 2019;10(1):85-94doi: 10.21037/jgo.2018.10.06.
Akce, M., Jiang, R., Alese, O. B., Shaib, W. L., Wu, C., Behera, M., & El-Rayes, B. F. (2019). Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. Journal of gastrointestinal oncology, 10(1), 85-94. https://doi.org/10.21037/jgo.2018.10.06
Akce, Mehmet, et al. "Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis." Journal of gastrointestinal oncology vol. 10,1 (2019): 85-94. doi: https://doi.org/10.21037/jgo.2018.10.06
Akce M, Jiang R, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF. Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. J Gastrointest Oncol. 2019 Feb;10(1):85-94. doi: 10.21037/jgo.2018.10.06. PMID: 30788163; PMCID: PMC6351299.
Copy Download .nbib Format: NLM
GAC: Gene Associations with Clinical, a web based application.

F1000Research

Zhang X, Rupji M, Kowalski J.
PMID: 29263780
F1000Res. 2017 Jul 03;6:1039. doi: 10.12688/f1000research.11840.4. eCollection 2017.

We present GAC, a shiny R based tool for interactive visualization of clinical associations based on high-dimensional data. The tool provides a web-based suite to perform supervised principal component analysis (SuperPC), an approach that uses both high-dimensional data, such...

Cite
Zhang X, Rupji M, Kowalski J. GAC: Gene Associations with Clinical, a web based application. F1000Res. 2017;6:1039doi: 10.12688/f1000research.11840.4.
Zhang, X., Rupji, M., & Kowalski, J. (2017). GAC: Gene Associations with Clinical, a web based application. F1000Research, 61039. https://doi.org/10.12688/f1000research.11840.4
Zhang, Xinyan, et al. "GAC: Gene Associations with Clinical, a web based application." F1000Research vol. 6 (2017): 1039. doi: https://doi.org/10.12688/f1000research.11840.4
Zhang X, Rupji M, Kowalski J. GAC: Gene Associations with Clinical, a web based application. F1000Res. 2017 Jul 03;6:1039. doi: 10.12688/f1000research.11840.4. eCollection 2017. PMID: 29263780; PMCID: PMC5658710.
Copy Download .nbib Format: NLM
Different Effect of .

Frontiers in genetics

Li Y, Struebing FL, Wang J, King R, Geisert EE.
PMID: 30619460
Front Genet. 2018 Dec 18;9:633. doi: 10.3389/fgene.2018.00633. eCollection 2018.

No abstract available.

Cite
Li Y, Struebing FL, Wang J, et al. Different Effect of . Front Genet. 2018;9:633doi: 10.3389/fgene.2018.00633.
Li, Y., Struebing, F. L., Wang, J., King, R., & Geisert, E. E. (2018). Different Effect of . Frontiers in genetics, 9633. https://doi.org/10.3389/fgene.2018.00633
Li, Ying, et al. "Different Effect of ." Frontiers in genetics vol. 9 (2018): 633. doi: https://doi.org/10.3389/fgene.2018.00633
Li Y, Struebing FL, Wang J, King R, Geisert EE. Different Effect of . Front Genet. 2018 Dec 18;9:633. doi: 10.3389/fgene.2018.00633. eCollection 2018. PMID: 30619460; PMCID: PMC6305287.
Copy Download .nbib Format: NLM
Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.

Bioorganic & medicinal chemistry

Yang X, Fan D, Troha AH, Ahn HM, Qian K, Liang B, Du Y, Fu H, Ivanov AA.
PMID: 34333394
Bioorg Med Chem. 2021 Sep 01;45:116324. doi: 10.1016/j.bmc.2021.116324. Epub 2021 Jul 22.

The transcription master regulator MYC plays an essential role in regulating major cellular programs and is a well-established therapeutic target in cancer. However, MYC targeting for drug discovery is challenging. New therapeutic approaches to control MYC-dependent malignancy are urgently...

Cite
Yang X, Fan D, Troha AH, et al. Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer. Bioorg Med Chem. 2021;45:116324doi: 10.1016/j.bmc.2021.116324.
Yang, X., Fan, D., Troha, A. H., Ahn, H. M., Qian, K., Liang, B., Du, Y., Fu, H., & Ivanov, A. A. (2021). Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer. Bioorganic & medicinal chemistry, 45116324. https://doi.org/10.1016/j.bmc.2021.116324
Yang, Xuan, et al. "Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer." Bioorganic & medicinal chemistry vol. 45 (2021): 116324. doi: https://doi.org/10.1016/j.bmc.2021.116324
Yang X, Fan D, Troha AH, Ahn HM, Qian K, Liang B, Du Y, Fu H, Ivanov AA. Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer. Bioorg Med Chem. 2021 Sep 01;45:116324. doi: 10.1016/j.bmc.2021.116324. Epub 2021 Jul 22. PMID: 34333394; PMCID: PMC8456368.
Copy Download .nbib Format: NLM
Whole-lung low-dose radiation therapy (LD-RT) for non-intubated oxygen-dependent patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesevir.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Hess CB, Eng TY, Nasti TH, Dhere VR, Kleber TJ, Switchenko JM, Weinberg BD, Rouphael N, Tian S, Rudra S, Taverna LS, Daisson AP, Ahmed R, Khan MK.
PMID: 34653525
Radiother Oncol. 2021 Dec;165:20-31. doi: 10.1016/j.radonc.2021.10.003. Epub 2021 Oct 13.

BACKGROUND: Low-dose radiotherapy (LD-RT) has produced anti-inflammatory effects in both animal models and early human trials of COVID-19-related pneumonia. The role of whole-lung LD-RT within existing treatment paradigms merits further study.METHODS: A phase II prospective trial studied the addition...

Cite
Hess CB, Eng TY, Nasti TH, et al. Whole-lung low-dose radiation therapy (LD-RT) for non-intubated oxygen-dependent patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesevir. Radiother Oncol. 2021;165:20-31doi: 10.1016/j.radonc.2021.10.003.
Hess, C. B., Eng, T. Y., Nasti, T. H., Dhere, V. R., Kleber, T. J., Switchenko, J. M., Weinberg, B. D., Rouphael, N., Tian, S., Rudra, S., Taverna, L. S., Daisson, A. P., Ahmed, R., & Khan, M. K. (2021). Whole-lung low-dose radiation therapy (LD-RT) for non-intubated oxygen-dependent patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesevir. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 16520-31. https://doi.org/10.1016/j.radonc.2021.10.003
Hess, Clayton B, et al. "Whole-lung low-dose radiation therapy (LD-RT) for non-intubated oxygen-dependent patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesevir." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 165 (2021): 20-31. doi: https://doi.org/10.1016/j.radonc.2021.10.003
Hess CB, Eng TY, Nasti TH, Dhere VR, Kleber TJ, Switchenko JM, Weinberg BD, Rouphael N, Tian S, Rudra S, Taverna LS, Daisson AP, Ahmed R, Khan MK. Whole-lung low-dose radiation therapy (LD-RT) for non-intubated oxygen-dependent patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesevir. Radiother Oncol. 2021 Dec;165:20-31. doi: 10.1016/j.radonc.2021.10.003. Epub 2021 Oct 13. PMID: 34653525; PMCID: PMC8511870.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 102 entries